Abstract
This issue features a set of articles addressing allocation issues for drugs for COVID-19 that have not been approved by the FDA but are available through either Emergency Use Authorization or Expanded Access Programs (EAP). Webb et al. (2020) propose a framework to guide these decisions. Of particular note, the authors point out that a requirement for EAP programs is that they do not interfere with clinical development, including clinical trials, and that the larger the number of participants, the greater the evidence required for an EAP.